SCHEMBL1399153

SCHEMBL1399153

N#Cc1ccccc1C=CC=CC(=O)N1CCN(c2cccc(Cl)c2)CC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.57
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
HTT P42858 1/20 0.53
MAPT P10636 2/20 0.49
HTR1A P08908 1/20 0.47
HTR2A P28223 1/20 0.47
HTR7 P34969 1/20 0.47
HTR6 P50406 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA9 Q16790 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.44
AKR1C3 P42330 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1399152 1.00 RAB9A (0.57) RAB9AALDH1A1KDM4ESMN1; SMN2HTT
SCHEMBL1399098 0.80 LMNA (0.56) RAB9AALDH1A1KDM4ESMN1; SMN2HTT
SCHEMBL1399100 0.80 LMNA (0.56) RAB9AALDH1A1KDM4ESMN1; SMN2HTT
SCHEMBL1399107 0.80 GAA (0.47) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL1399105 0.80 GAA (0.47) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL1399168 0.78 KDM4E (0.54) ALDH1A1KDM4ESMN1; SMN2HTTMAPT
SCHEMBL1399056 0.78 KDM4E (0.54) ALDH1A1KDM4ESMN1; SMN2HTTMAPT
SCHEMBL1399049 0.76 F2R (0.39) MAPTMEN1KMT2AL3MBTL1
SCHEMBL1399051 0.76 F2R (0.39) MAPTMEN1KMT2AL3MBTL1
SCHEMBL1399035 0.75 F2R (0.44) ALDH1A1KDM4ESMN1; SMN2MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022064-B2 Phenylpentadienoyl derivatives and their use as PAR 1 antagonists PIERRE FABRE MEDICAMENT (FR) 2011-09-20 US claimed
EP-2046748-B1 PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS PF MEDICAMENT (FR) 2011-03-02 EP claimed
US-20100003260-A1 PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS PIERRE FABRE MEDICAMENT (FR) 2010-01-07 US claimed
EP-2046748-B1 PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS PF MEDICAMENT (FR) 2011-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100003260-A1 PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS F2R, F2RL1, FPR1 RAB9A 2764/4885ALDH1A1 1195/4885KDM4E 4084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.